Johnson And Johnson (JNJ) vs Pfizer (PFE)
JNJ and PFE are tied on the current QuantLink comparison, so the scorecard does not point to a single leader.
Side-by-side scorecard
As of Aug 25, 2026. Unavailable values are shown as — and excluded from the comparable-metric tally.
| Metric | Johnson & Johnson (JNJ) | Pfizer Inc. (PFE) |
|---|---|---|
| Size | ||
PriceContext only | — | — |
Market capContext only | $658.2B | $162.8B |
| Valuation | ||
P/E ratio | ✓31.62x | 37.50x |
PEG ratio | ✓-3.88x | -0.63x |
Price/book | 7.83x | ✓1.91x |
Price/sales | 6.79x | ✓2.55x |
EV/EBITDA | 20.34x | ✓17.00x |
| Profitability | ||
Gross margin | 70.5% | ✓71.3% |
Operating margin | ✓26.8% | 25.1% |
Net margin | ✓21.5% | 6.8% |
ROIC | — | 4.7% |
ROE | — | 5.1% |
EPS | — | — |
| Leverage | ||
Debt/equity | — | 0.74x |
| Dividend | ||
Dividend yield | — | — |
How the comparison is scored
QuantLink marks a row leader only when both companies have a numeric value and the metric has a fixed comparison direction. Lower values lead on valuation multiples and debt/equity, while higher values lead on profitability and dividend yield.
Price and market capitalization are shown for context only, so they do not receive a leader checkmark and do not affect the tally.